1. Home
  2. ZIP vs NNNN Comparison

ZIP vs NNNN Comparison

Compare ZIP & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZIP

ZipRecruiter Inc.

HOLD

Current Price

$4.48

Market Cap

317.9M

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$3.28

Market Cap

270.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZIP
NNNN
Founded
2010
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.9M
270.4M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
ZIP
NNNN
Price
$4.48
$3.28
Analyst Decision
Hold
Analyst Count
5
0
Target Price
★ $4.75
N/A
AVG Volume (30 Days)
★ 571.0K
89.5K
Earning Date
11-04-2026
10-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.46
N/A
Revenue
★ $448,952,000.00
N/A
Revenue This Year
$2.98
N/A
Revenue Next Year
$5.06
N/A
P/E Ratio
★ $9.62
$446.57
Revenue Growth
N/A
★ N/A
52 Week Low
$1.65
$3.09
52 Week High
$5.61
$44.73

Technical Indicators

Market Signals
Indicator
ZIP
NNNN
Relative Strength Index (RSI) 58.99 26.22
Support Level $3.61 N/A
Resistance Level $4.60 $6.95
Average True Range (ATR) 0.26 0.50
MACD 0.11 -0.12
Stochastic Oscillator 68.21 9.58

Price Performance

Historical Comparison
ZIP
NNNN

About ZIP ZipRecruiter Inc.

ZipRecruiter Inc is an online employment marketplace that connects job seekers and employers through an AI-powered platform. The company provides recruiting solutions that help employers identify and hire qualified candidates while enabling job seekers to discover relevant job opportunities through intelligent matching and recommendation tools.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: